Found: 78
Select item for more details and to access through your institution.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 25, doi. 10.1002/ajh.21912
- By:
- Publication type:
- Article
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 4, p. 628, doi. 10.1111/ejh.14057
- By:
- Publication type:
- Article
Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 2, p. 222, doi. 10.1111/ejh.13896
- By:
- Publication type:
- Article
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 3, p. 318, doi. 10.1111/ejh.13666
- By:
- Publication type:
- Article
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 6, p. 621, doi. 10.1111/ejh.13058
- By:
- Publication type:
- Article
Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 4, p. 311, doi. 10.3816/CLM.2009.n.061
- By:
- Publication type:
- Article
Proteasome Inhibitors: Closing the Garbage Can Opens up New Therapeutic Options for Patients with B-Cell Malignancies.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, p. S182
- By:
- Publication type:
- Article
Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 5, p. 346
- By:
- Publication type:
- Article
Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 3, p. 192
- By:
- Publication type:
- Article
The Van Poznak/Estilo Article Reviewed.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 9, p. 1065
- By:
- Publication type:
- Article
Removal of a Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report.
- Published in:
- Case Reports in Oncology, 2020, v. 13, n. 3, p. 1103, doi. 10.1159/000508494
- By:
- Publication type:
- Article
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.
- Published in:
- International Journal of Oncology, 2014, v. 45, n. 3, p. 1184, doi. 10.3892/ijo.2014.2511
- By:
- Publication type:
- Article
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 523, doi. 10.1016/j.clml.2022.01.012
- By:
- Publication type:
- Article
Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 2, doi. 10.1016/j.clml.2011.03.025
- By:
- Publication type:
- Article
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma.
- Published in:
- Cancer Reports, 2023, v. 6, n. 5, p. 1, doi. 10.1002/cnr2.1803
- By:
- Publication type:
- Article
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2016, v. 108, n. 3, p. 1, doi. 10.1093/jnci/djv342
- By:
- Publication type:
- Article
Phase I/ II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 3, p. 321, doi. 10.1111/bjh.12129
- By:
- Publication type:
- Article
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 6, p. 727, doi. 10.1111/j.1365-2141.2012.09241.x
- By:
- Publication type:
- Article
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 5, p. 580, doi. 10.1111/j.1365-2141.2011.08884.x
- By:
- Publication type:
- Article
Monoclonal gammopathy of undetermined significance: a consensus statement.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 1, p. 28, doi. 10.1111/j.1365-2141.2010.08207.x
- By:
- Publication type:
- Article
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 4, p. 569, doi. 10.1111/j.1365-2141.2009.08008.x
- By:
- Publication type:
- Article
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2008, v. 143, n. 4, p. 537, doi. 10.1111/j.1365-2141.2008.07359.x
- By:
- Publication type:
- Article
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
- Published in:
- British Journal of Haematology, 2007, v. 138, n. 4, p. 467, doi. 10.1111/j.1365-2141.2007.06675.x
- By:
- Publication type:
- Article
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 2, p. 174, doi. 10.1111/j.1365-2141.2006.06280.x
- By:
- Publication type:
- Article
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.
- Published in:
- British Journal of Haematology, 2006, v. 133, n. 5, p. 526, doi. 10.1111/j.1365-2141.2006.06052.x
- By:
- Publication type:
- Article
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 5, p. 439, doi. 10.1111/ejh.12748
- By:
- Publication type:
- Article
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 3, p. 201, doi. 10.1111/j.1600-0609.2009.01384.x
- By:
- Publication type:
- Article
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
- Published in:
- European Journal of Haematology, 2009, v. 82, n. 6, p. 433, doi. 10.1111/j.1600-0609.2009.01244.x
- By:
- Publication type:
- Article
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable.
- Published in:
- European Journal of Haematology, 2003, v. 70, n. 4, p. 263, doi. 10.1034/j.1600-0609.2003.t01-2-00011.x
- By:
- Publication type:
- Article
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. 722, doi. 10.1111/bjh.18593
- By:
- Publication type:
- Article
Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1064, doi. 10.1111/bjh.16673
- By:
- Publication type:
- Article
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 568, doi. 10.1111/bjh.17282
- By:
- Publication type:
- Article
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 2, p. 272, doi. 10.1111/bjh.16752
- By:
- Publication type:
- Article
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 283, doi. 10.1111/bjh.16158
- By:
- Publication type:
- Article
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 60, doi. 10.1111/bjh.14992
- By:
- Publication type:
- Article
Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 1, p. 81, doi. 10.1111/bjh.14026
- By:
- Publication type:
- Article
Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies.
- Published in:
- 2012
- By:
- Publication type:
- journal article
A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 4, p. 336, doi. 10.1016/j.clml.2011.02.002
- By:
- Publication type:
- Article
Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 9, p. 484
- By:
- Publication type:
- Article
The Role of JAK Inhibitors in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 9, p. 500
- By:
- Publication type:
- Article
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2014, v. 5, n. 6, p. 197, doi. 10.1177/2040620714552614
- By:
- Publication type:
- Article
The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic.
- Published in:
- American Journal of Clinical Pathology, 2024, v. 161, n. 1, p. 16, doi. 10.1093/ajcp/aqad103
- By:
- Publication type:
- Article
MODELS FOR SYNGENEIC ADOPTIVE CHEMOIMMUNOTHERAPY OF MURINE LEUKEMIAS*.
- Published in:
- Annals of the New York Academy of Sciences, 1976, v. 276, n. 1, p. 573, doi. 10.1111/j.1749-6632.1976.tb41684.x
- By:
- Publication type:
- Article
Cryoglobulinemia: Better Treatments With Brighter Outcomes.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 578, doi. 10.1002/hon.3071
- By:
- Publication type:
- Article